To evaluate the safety, tolerability, and ac ceptability of zidovudine used for prevention of human immunodeficiency virus (HIV) transmission to health care workers.
Prospective study between January 1989 and December 1992 at a suburban New York City medical center of health care workers who had percutaneous or permucosal exposures to blood or body fluids of HIV-infected patients.
The zidovudine regimen offered was 200 mg orally every 4 hours for 42 days.
Only 60 (53%) of 113 health care workers chose to take zidowdine, and only 21 (35%) of these health care workers completed the recommended 42-day course of therapy.
Mots-clés Pascal : SIDA, Virose, Infection, Zidovudine, Profession, Santé, Maladie professionnelle, Chimiothérapie, Traitement, Prévention, Homme, Tolérance, Antiviral, Immunopathologie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Profession, Health, Occupational disease, Chemotherapy, Treatment, Prevention, Human, Tolerance, Antiviral, Immunopathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0082319
Code Inist : 002B02S05. Création : 09/06/1995.